Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals (ELOX) Misses Q4 EPS by 6c

March 8, 2019 7:02 AM EST

Eloxx Pharmaceuticals (NASDAQ: ELOX) reported Q4 EPS of ($0.40), $0.06 worse than the analyst estimate of ($0.34).

We are very pleased to be advancing ELX-02 in cystic fibrosis and look forward to reporting top line data from our Phase 2 clinical trial in the U.S. and... More